Literature DB >> 11207635

The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy.

M F Prummel1, M N Gerding, F W Zonneveld, W M Wiersinga.   

Abstract

BACKGROUND: Two-thirds of patients with Graves' ophthalmopathy (GO) respond to immunosuppressive treatment (prednisone or orbital irradiation), but one-third do not respond. Responders are likely to be in the active, oedematous stage of the eye disease, nonresponders in the inactive fibrotic stage. Clinical distinction between the two stages can be difficult. Quantitative magnetic resonance imaging (MRI) might be helpful in this respect, as T2 relaxation times are longer in oedematous than in fibrotic tissues. STUDY
DESIGN: Prospective study on quantitative orbital MRI in healthy subjects and patients with moderately severe GO, evaluating T2 relaxation time of extraocular muscles (EOM): (a) in patients vs. controls, and (b) in patients, as a predictor of outcome to orbital irradiation. SUBJECTS AND MEASUREMENTS: Nine healthy volunteers and 64 consecutive patients with moderately severe untreated GO, who were euthyroid for > or = 2 months and qualified for orbital irradiation. T2 relaxation times were measured at the site of the largest diameter in all eight EOM of each subject. Baseline T2 values in patients were related to outcome of radiotherapy, as assessed by an independent observer 6 months later according to predefined criteria.
RESULTS: T2 relaxation times of the eight EOM were longer in GO patients than in controls: median [range] 126 [52--250] vs. 88 [50--126] msec; P = 0.003. Per subject the single eye muscle with the longest T2 time was selected to represent active inflammation (excluding the lateral muscles for technical reasons). Again patients were different from controls: 160 [68--250] vs. 103 [86--115] msec, P < 0.001. In the group of 34 responders to subsequent radiotherapy, these T2 times tended to be longer than in the 30 nonresponding patients: 168 [108--250] vs. 138 [68--216] msec, P = 0.07. Using a cut-off value of 130 msec (derived from a receiver-operator-characteristics curve) a positive predictive value of 64% and a negative predictive value of 92% for the outcome of radiotherapy was calculated.
CONCLUSION: Quantitative orbital magnetic resonance imaging was found to be less accurate in predicting successful outcome of radiotherapy than expected. It seems more useful in detecting the fibrotic end-stage than the active stage of Graves' ophthalmopathy. It is therefore of limited use in the decision whether or not to apply immunosuppression in patients with moderately severe Graves' ophthalmopathy.

Entities:  

Mesh:

Year:  2001        PMID: 11207635     DOI: 10.1046/j.1365-2265.2001.01220.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Semiautomatic regional segmentation to measure orbital fat volumes in thyroid-associated ophthalmopathy. A validation study.

Authors:  M Comerci; A Elefante; D Strianese; R Senese; P Bonavolontà; B Alfano; B Bonavolontà; A Brunetti
Journal:  Neuroradiol J       Date:  2013-08-27

3.  Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg.

Authors:  Letterio Salvatore Politi; Claudia Godi; Gabriella Cammarata; Alessandro Ambrosi; Antonella Iadanza; Roberto Lanzi; Andrea Falini; Stefania Bianchi Marzoli
Journal:  Eur Radiol       Date:  2014-02-12       Impact factor: 5.315

4.  [A novel method for quantitative measurement of orbital fat volume based on magnetic resonance images].

Authors:  Qiu-Yue Cai; Zhi-Yi Chen; Wei Jiang; Yao-Sheng Luo; Zhang-Fang Li; Shi-di Hu; Jie Shen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-09-20

5.  Diagnostic accuracy of short-time inversion recovery sequence in Graves' Ophthalmopathy before and after prednisone treatment.

Authors:  Fabio Tortora; Mariaevelina Prudente; Mario Cirillo; Andrea Elefante; Maria Paola Belfiore; Francesco Romano; Salvatore Cappabianca; Carlo Carella; Sossio Cirillo
Journal:  Neuroradiology       Date:  2014-02-27       Impact factor: 2.804

6.  Disease activity in Graves' ophthalmopathy: diagnosis with orbital MR imaging and correlation with clinical score.

Authors:  Fabio Tortora; Mario Cirillo; Marco Ferrara; Maria Paola Belfiore; Carlo Carella; Ferdinando Caranci; Sossio Cirillo
Journal:  Neuroradiol J       Date:  2013-11-07

7.  Orbital Fat Volumetry and Water Fraction Measurements Using T2-Weighted FSE-IDEAL Imaging in Patients with Thyroid-Associated Orbitopathy.

Authors:  Y Kaichi; K Tanitame; H Itakura; H Ohno; M Yoneda; Y Takahashi; Y Akiyama; K Awai
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-30       Impact factor: 3.825

8.  Non-EPI-DWI for Detection, Disease Monitoring, and Clinical Decision-Making in Thyroid Eye Disease.

Authors:  C Feeney; R K Lingam; V Lee; F Rahman; S Nagendran
Journal:  AJNR Am J Neuroradiol       Date:  2020-08       Impact factor: 3.825

9.  Advances in magnetic resonance imaging of orbital disease.

Authors:  Rebecca E Tanenbaum; Remy Lobo; Alon Kahana; Sara T Wester
Journal:  Can J Ophthalmol       Date:  2021-05-28       Impact factor: 2.592

10.  Signal intensity and T2 time of extraocular muscles in assessment of their physiological status in MR imaging in healthy subjects.

Authors:  Michał Pająk; Piotr Loba; Julia Wieczorek-Pastusiak; Aneta Antosik-Biernacka; Ludomir Stefańczyk; Agata Majos
Journal:  Pol J Radiol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.